Not Yet Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06345027

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) (CASEY)

Sponsor: Baylor College of Medicine

Conditions Leukemia, B-cell Leukemia, Myeloid, Acute Leukemia, T-Cell

Updated 6 times since 2024 Last updated: Dec 9, 2025 Started: Feb 28, 2026 Primary completion: May 31, 2027 Completion: Apr 1, 2042

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Leukemia, B-cell and Leukemia, Myeloid, Acute and is currently actively recruiting participants. Baylor College of Medicine leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Not Yet Recruiting PHASE1
Aug 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE1
Nov 2024 — Aug 2025 [monthly]

Not Yet Recruiting PHASE1
Sep 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1

▶ Show 1 earlier version

May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Baylor College of Medicine

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States